Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. These regulatory documents offer detailed information on the company’s financial condition, clinical development activities, risk factors and corporate governance.
Through periodic reports such as Forms 10-Q and 10-K, Pliant describes research and development spending, progress in programs like bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis, PLN-101095 for solid tumors and PLN-101325 for muscular dystrophies, as well as broader platform efforts in integrin-based drug discovery. Current reports on Form 8-K, including those referenced in the provided data, disclose specific material events such as financial results for a quarter, voluntary prepayment and termination of a loan agreement, changes in executive leadership roles and other significant corporate actions.
Investors can also review filings that discuss strategic realignments of workforce and operations, cash runway considerations and references to risk factors and management’s discussion and analysis sections, which Pliant points to in its press releases. For those tracking equity and governance details, the company’s registration of common stock and related rights on The Nasdaq Stock Market LLC is reflected in its SEC submissions.
On Stock Titan, these filings are available alongside AI-powered summaries that highlight key points, helping readers interpret lengthy documents such as annual and quarterly reports or event-driven 8-Ks. Real-time updates from the SEC’s EDGAR system, combined with structured access to filings related to financial results, material agreements and leadership changes, allow users to follow how Pliant’s disclosures develop over time.
Pliant Therapeutics reported an executive change: Chief Business Officer Hans Hull resigned effective October 20, 2025. The company stated the resignation was not due to any disagreement related to operations, policies, or practices. The report was signed by Keith Cummings, M.D., MBA, in his capacity as Chief Financial Officer.
Pliant Therapeutics, Inc. (PLRX) fully repaid its debt facility, making a voluntary payoff of $32.4 million on October 14, 2025 to settle all outstanding principal, accrued interest, fees and expenses under its Amended and Restated Loan and Security Agreement with Oxford Finance. With receipt of the payoff, all obligations were discharged and the loan documents were terminated.
The agreement allowed up to $150 million in term loans; the company had borrowed $30 million. The loans bore a floating rate tied to 1‑month SOFR with a 3.5% add‑on plus 5.25%, subject to a floor of 8.75%. Scheduled amortization would have begun on July 1, 2028, but the company chose early repayment, eliminating future interest and covenant requirements tied to this facility.
Point72 Asset Management and affiliates report beneficial ownership of 4,085,017 shares of Pliant Therapeutics, Inc. (PLRX), representing 6.7% of the outstanding common stock as of the close of business on September 3, 2025. The filing is a Schedule 13G showing that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen share voting and dispositive power over these shares and that the shares are held by an investment fund managed by Point72 Asset Management (Point72 Associates).
The statement clarifies that none of the reporting persons own shares directly and that Point72 Associates has the right to receive dividends or sale proceeds for more than 5% of the class. A Joint Filing Agreement (Exhibit 99.1) is referenced.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin together report owning 3,947,807 shares of Pliant Therapeutics common stock, equal to 6.43% of the company’s outstanding shares. The filing is a Schedule 13G/A (Amendment No. 2) disclosing shared voting and dispositive power over those shares, with no sole voting or dispositive power reported.
The ownership amount is calculated using 61,386,278 shares outstanding as of May 1, 2025, per the issuer’s May 8, 2025 SEC filing. The signatories certify the shares were not acquired to change or influence control of the issuer. Signatures are dated August 14, 2025.
Morgan Stanley has filed a Schedule 13G revealing ownership of 3,737,335 Pliant Therapeutics (PLRX) common shares as of 30 Jun 2025. The stake equals 6.1 % of outstanding stock, obligating disclosure under the 5 % threshold. All voting and dispositive authority is reported as shared; the bank holds zero sole voting or disposal power, implying the position is spread across affiliated units.
The form was submitted under Rule 13d-1(b), indicating a passive investment rather than an activist intent. Morgan Stanley is classified as a “HC, CO” (parent holding company/control person). The firm certifies the shares were acquired in the ordinary course of business and not to influence control of the issuer. No other group members, transactions, or financial metrics are disclosed.
This filing adds a notable institutional holder to PLRX’s register, potentially boosting liquidity and visibility but contains no information on company fundamentals or strategy changes.